Loading...
Bilateral Trade Intelligence · $2.1M Total Trade · 31 Exporters · 34 Buyers · DGFT Verified · Updated March 2026
India exported $2.1M worth of pharmaceutical formulations to Uruguay across 192 verified shipments, sourced from 31 Indian exporters supplying 34 Uruguay buyers. The top exporters are CIPLA LIMITED ($382.8K) and GRANULES INDIA LIMITED ($360.7K). The leading products are Dolutegravir ($294K) and Tacrolimus ($137K). Average shipment value: $11.1K.
| # | Formulation | Value | Share |
|---|---|---|---|
| 1 | Dolutegravir Cipla 50mg Tablet (dolutegravir 50mg) | $294.4K | 13.9% |
| 2 | Compresso Pap 90cpc(paracetamol/acetaminophen Granules Dc 90 %) | $178.5K | 8.4% |
| 3 | Material No. - 44098110 Tacrolimus Sdz 1mg 100hgc Uy | $136.9K | 6.4% |
| 4 | Heparin Injection Bp,25000iu/5ml, 5ml Vial | $115.6K | 5.4% |
| 5 | Losartan 50mg X 30 Comp Uruguay (emil) Losartan Potassium Tablets 50 Mg,lic.-mh… | $108.8K | 5.1% |
| 6 | Losartan Opko 50mg X 30 Comp (uru) Losartan Potassium Tablets 50 Mg,lic.-mh/dru… | $89.0K | 4.2% |
| 7 | Tiova 18mcg Rotacaps (18560 Packs X1x30s= 556800 ) | $74.9K | 3.5% |
| 8 | Lopinavir 200 MG Ritonavir 50 MG Macleods Bno. 14250342a & 14250118c Mfg Dt:01/… | $68.7K | 3.2% |
| 9 | Compresso Ibu 90 Cp | $67.8K | 3.2% |
| 10 | Drugs and Pharmaceuticals Harmlessmedicines Tenofovir Disoproxil Fumarate Table… | $65.2K | 3.1% |
| 11 | Pharmaceutical Product Elaxim 50 MG Injection Tnk-t-pa (tenecteplase 50mg in | $63.3K | 3.0% |
| 12 | Compresso Mf 95p | $48.4K | 2.3% |
| 13 | Material No. -44098110, Tacrolimus Sdz 1mg 100hgc Uy, Batch No.ph7018 Mfg Date:… | $48.3K | 2.3% |
| 14 | Capecitabine Tablets USP 500 MG (capzat 500 Mg)(tax Inv# Mh2411600562 Dt. 17.02… | $48.2K | 2.3% |
| 15 | Contraceptive Based On Other Product of Heading 2937 Namely -intrauterine Contr… | $45.3K | 2.1% |
India exports 20+ pharmaceutical formulations to Uruguay with a combined trade value of $2.1M. Key products include Dolutegravir ($294K), Tacrolimus ($137K), Heparin ($116K), Losartan ($109K), Ritonavir ($69K). These are finished dosage forms — tablets, capsules, injectables, and combination drugs — shipped from Indian manufacturing facilities with FDA, WHO-GMP, and EU GMP certifications. Data from 192 verified Indian Customs (DGFT) shipment records.
Historical evolution, India's market position, and recent developments
The pharmaceutical trade between India and Uruguay has experienced steady growth over the past decade. In 2024, India's pharmaceutical exports to Uruguay were valued at approximately $4.32 million, marking a significant increase from previous years. This upward trajectory underscores the strengthening bilateral trade relations and India's expanding footprint in the Latin American pharmaceutical market.
Key milestones in this trade corridor include the establishment of direct shipping routes and the initiation of joint ventures between Indian pharmaceutical companies and Uruguayan distributors. These collaborations have facilitated smoother logistics and enhanced market penetration. The consistent growth reflects India's strategic focus on diversifying its export markets and Uruguay's growing demand for affordable, high-quality pharmaceutical products.
India holds a significant position in Uruguay's pharmaceutical import landscape. In 2024, India's pharmaceutical exports to Uruguay were valued at $4.32 million, contributing to Uruguay's total pharmaceutical imports of $444 million. This positions India as a key supplier, accounting for approximately 1% of Uruguay's pharmaceutical imports. While other countries, notably the United States, also export pharmaceuticals to Uruguay, India's competitive pricing and diverse product range enhance its strategic importance in the Uruguayan market.
These are the top pharmaceutical products exported from India to Uruguay, each with a dedicated trade route analysis page. Click any product to see detailed export data including Indian suppliers, Uruguay buyers, regulatory requirements, and logistics for that specific product corridor. Products include Dolutegravir ($294K), Tacrolimus ($137K), Heparin ($116K), Losartan ($109K), Ritonavir ($69K) — all finished pharmaceutical formulations verified from Indian Customs (DGFT) records.
31 Indian pharmaceutical companies export finished formulations to Uruguay. Leading exporters include Cipla Limited, Granules India Limited, Sandoz Private Limited, Emil Pharmaceutical Industries Pvt Ltd. The top exporter accounts for 18.0% of total India–Uruguay pharma exports. Source: Indian Customs (DGFT).
34 companies in Uruguay import pharmaceutical formulations from India. Top buyers include Servimedic Sa, Opko Uruguay Ltda., Szabo S.a, Business Modena Sa. The largest buyer accounts for 18.0% of India–Uruguay pharma imports. Source: Indian Customs (DGFT).
Between 2024 and 2026, several developments have influenced the India-Uruguay pharmaceutical trade. In 2025, India's pharmaceutical exports to Uruguay experienced a notable increase, reflecting the strengthening bilateral trade relations. Additionally, Uruguay's regulatory framework has evolved to align more closely with international standards, streamlining the approval process for foreign pharmaceutical products. These changes have facilitated smoother market entry for Indian exporters, contributing to the growth of this trade corridor.
EXPORT_REGULATORY
Registration process, GMP requirements, import documentation
Indian pharmaceutical companies seeking to register products in Uruguay must adhere to the guidelines set by the Ministry of Public Health (Ministerio de Salud Pública – MSP). The registration process involves submitting a comprehensive dossier that includes the product's composition, therapeutic indications, manufacturing process, quality control measures, clinical evidence, labeling, and safety profile. This documentation ensures that the product meets Uruguay's health and safety standards. (vui.gub.uy)
The dossier should be prepared in accordance with the Common Technical Document (CTD) format, which is internationally recognized and facilitates the evaluation process. Additionally, products must comply with Good Manufacturing Practice (GMP) standards as recognized by the World Health Organization (WHO). This includes providing valid GMP certificates from internationally accepted regulatory bodies. The timeline for product registration can vary, but companies should anticipate a process that may take several months, depending on the completeness of the submitted documentation and the efficiency of the regulatory review.
Uruguay requires that pharmaceutical products imported into the country be manufactured in facilities that comply with Good Manufacturing Practice (GMP) standards. These standards ensure that products are consistently produced and controlled according to quality standards. Indian manufacturers must provide valid GMP certificates issued by recognized health authorities in their country of origin as part of the product registration process.
The inspection process involves a thorough evaluation of the manufacturing facility to verify compliance with GMP standards. Uruguay's regulatory authorities may conduct inspections or request documentation to confirm adherence to these standards. While Uruguay is not a member of the World Health Organization's (WHO) Pharmaceutical Inspection Co-operation Scheme (PIC/S), it recognizes GMP certifications from countries with established regulatory frameworks. Therefore, Indian manufacturers with WHO-GMP certification are well-positioned to meet Uruguay's requirements.
To import pharmaceutical products into Uruguay, companies must obtain prior approval from the Ministry of Public Health (MSP). This involves submitting a customs declaration to the National Directorate of Customs (Dirección Nacional de Aduanas), providing detailed information for fiscal, statistical, and regulatory processing of the import.
Additionally, a product registration dossier must be submitted, covering the product’s composition, therapeutic purpose, manufacturing process, quality control, clinical evidence, labeling, and safety profile. Good Manufacturing Practice (GMP) certificates from recognized health authorities in the country of origin are also required. An insurance certificate may be necessary to cover potential liabilities associated with the product. These requirements ensure that imported pharmaceutical products meet Uruguay's health and safety standards.
EXPORT_TRENDS
Dominant categories, emerging opportunities, and demand drivers
India's pharmaceutical exports to Uruguay are predominantly composed of finished pharmaceutical formulations, including tablets, capsules, syrups, and injections. This aligns with Uruguay's healthcare needs, as the country relies on imported finished dosage forms to meet the demands of its healthcare system. The therapeutic areas covered by these products are diverse, addressing conditions such as infectious diseases, cardiovascular disorders, and chronic illnesses. The presence of Indian pharmaceutical products in these categories enhances the availability of essential medicines in Uruguay, contributing to improved healthcare outcomes.
The global pharmaceutical industry is witnessing significant developments, including the expiration of patents for several blockbuster drugs and the increasing demand for biosimilars. These trends present emerging opportunities for Indian pharmaceutical exporters in Uruguay. By leveraging its expertise in generic drug manufacturing, India can supply cost-effective alternatives to patented medications, catering to the needs of the Uruguayan market. Additionally, the growing interest in biosimilars offers a platform for Indian companies to introduce these products, capitalizing on Uruguay's evolving healthcare landscape.
Uruguay's pharmaceutical import demand is driven by several factors, including its disease burden, aging population, and healthcare spending trends. The country faces challenges related to chronic diseases, infectious diseases, and an aging demographic, all of which contribute to increased demand for pharmaceutical products. Additionally, Uruguay's commitment to improving healthcare infrastructure and expanding access to medicines further drives the need for imported pharmaceuticals. These factors create a conducive environment for Indian pharmaceutical exporters to meet the growing demands of the Uruguayan market.
EXPORT_POLICY
Tariff structure, trade agreements, IP and patent landscape
Uruguay's tariff and duty structure for pharmaceutical products is influenced by its commitments under the World Trade Organization's (WTO) Pharmaceutical Agreement. This agreement aims to eliminate tariffs and other duties on a wide range of pharmaceutical products and the substances used to produce them, binding them at duty-free levels. As a result, pharmaceutical products imported into Uruguay benefit from reduced or zero tariffs, enhancing the competitiveness of Indian exports in the Uruguayan market.
Uruguay is a member of the Southern Common Market (MERCOSUR), a regional trade bloc that includes Argentina, Brazil, Paraguay, and Venezuela. MERCOSUR has established trade agreements with various countries and regions, aiming to promote economic integration and facilitate trade among member states. While there is no specific Free Trade Agreement (FTA) between India and MERCOSUR, the existing trade agreements within MERCOSUR may indirectly benefit Indian pharmaceutical exporters by reducing trade barriers and enhancing market access.
Uruguay's intellectual property (IP) and patent landscape is aligned with international standards, including those set by the World Trade Organization's Trade-Related Aspects of Intellectual Property Rights (TRIPS) Agreement. This framework provides protection for patents, data exclusivity, and addresses issues related to compulsory licensing. For Indian generic pharmaceutical companies, understanding Uruguay's IP regulations is crucial to navigate the market effectively and ensure compliance with local laws.
EXPORT_LOGISTICS
Shipping routes, port infrastructure, cold chain compliance
Shipping pharmaceutical products from India to Uruguay involves both sea and air routes. Major Indian ports, such as Mumbai and Chennai, serve as primary departure points. Sea freight typically involves transshipment through hubs like Singapore or Dubai, with transit times ranging from 30 to 45 days, depending on the specific route and shipping conditions. Air freight offers faster delivery, with transit times of approximately 7 to 10 days, though it is more costly. It's essential to monitor global shipping conditions, as disruptions in key routes can impact delivery schedules.
In India, major export ports include Sahar Air Cargo Complex (INBOM4), Nhava Sheva Sea Port (INNSA1), and Irungattukottai ICD (INILP6). In Uruguay, key import ports are Montevideo, Santa Cruz, and other facilities. These ports are equipped to handle pharmaceutical shipments, ensuring compliance with international standards for cargo handling and storage. Efficient port operations are crucial for maintaining the integrity and timely delivery of pharmaceutical products.
Maintaining the cold chain is critical for the integrity of temperature-sensitive pharmaceutical products. Indian exporters must ensure that their logistics partners adhere to Good Distribution Practice (GDP)
India exported pharmaceuticals worth $2.1M to Uruguay across 192 verified shipments.
1. CIPLA LIMITED — $382.8K. 2. GRANULES INDIA LIMITED — $360.7K. 3. SANDOZ PRIVATE LIMITED — $218.1K. Total: 31 suppliers.
1. SERVIMEDIC SA — $382.8K. 2. OPKO URUGUAY LTDA. — $197.8K. 3. SZABO S.A — $178.5K. 34 buyers total.
1. Dolutegravir Cipla 50mg Tablet (dolutegravir 50mg) ($294.4K, 13.9%); 2. Compresso Pap 90cpc(paracetamol/acetaminophen Granules Dc 90 %) ($178.5K, 8.4%); 3. Material No. - 44098110 Tacrolimus Sdz 1mg 100hgc Uy ($136.9K, 6.4%); 4. Heparin Injection Bp,25000iu/5ml, 5ml Vial ($115.6K, 5.4%); 5. Losartan 50mg X 30 Comp Uruguay (emil) Losartan Potassium Tablets 50 Mg,lic.-mh… ($108.8K, 5.1%)
Export: SAHAR AIR CARGO ACC (INBOM4), NHAVA SHEVA SEA (INNSA1), IRUNGATTUKOTTAI ICD (INILP6), HYDERABAD ICD (INSNF6), HYDERABAD ACC (INHYD4). Import: MONTEVIDEO -, Montevideo, Santa Cruz.
India's cost-competitive generic drug manufacturing, WHO-GMP certified facilities, and broad product portfolio. This $2.1M corridor reflects quality compliance and pricing advantages.
WHO-GMP certification, EU GMP approval (for EU markets), product dossier registration (CTD format), and ICH guideline compliance.
$11.1K per consignment across 192 shipments.
31 Indian companies. Largest: CIPLA LIMITED with $382.8K.
TransData Nexus covers 31 active exporters with shipment history and trade values at transdatanexus.com.
Access complete shipment records, supplier intelligence, buyer histories, and price analytics for all 192 shipments.
Data sourced from Indian Customs (DGFT) records. Verify regulatory status with the agencies above.
Pharmaceutical Export-Import Analyst & Trade Intelligence Expert
Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.
linkedin.com/in/sureshsormareAll trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.
Government-Sourced Data
Official DGFT customs records
Transparent Methodology
Calculations fully disclosed above
31 Exporters
34 buyers tracked
Expert-Reviewed
By pharmaceutical trade specialists